MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Cuts Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. reduced its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 2.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,327 shares of the company’s stock after selling 498 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.05% of Mirum Pharmaceuticals worth $1,006,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MIRM. Janus Henderson Group PLC raised its position in Mirum Pharmaceuticals by 2.3% in the 4th quarter. Janus Henderson Group PLC now owns 4,581,642 shares of the company’s stock valued at $189,481,000 after purchasing an additional 101,358 shares in the last quarter. D. E. Shaw & Co. Inc. acquired a new stake in Mirum Pharmaceuticals in the fourth quarter valued at approximately $6,507,000. Deutsche Bank AG lifted its stake in Mirum Pharmaceuticals by 7.7% in the fourth quarter. Deutsche Bank AG now owns 169,323 shares of the company’s stock worth $7,002,000 after acquiring an additional 12,060 shares during the last quarter. Boone Capital Management LLC lifted its stake in Mirum Pharmaceuticals by 7.0% in the fourth quarter. Boone Capital Management LLC now owns 581,843 shares of the company’s stock worth $24,059,000 after acquiring an additional 38,000 shares during the last quarter. Finally, Bosun Asset Management LLC grew its holdings in Mirum Pharmaceuticals by 45.5% during the 4th quarter. Bosun Asset Management LLC now owns 10,413 shares of the company’s stock worth $431,000 after acquiring an additional 3,256 shares in the last quarter.

Analyst Ratings Changes

Several research firms recently weighed in on MIRM. JMP Securities boosted their target price on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a “market outperform” rating in a research note on Friday, May 9th. Robert W. Baird upped their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $73.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. Finally, Raymond James reissued a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 13th. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $60.73.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 57,606 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.35, for a total value of $2,554,826.10. Following the transaction, the senior vice president now directly owns 4,841 shares in the company, valued at $214,698.35. The trade was a 92.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Patrick J. Heron purchased 1,335 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average price of $45.57 per share, for a total transaction of $60,835.95. Following the completion of the transaction, the director now owns 163,643 shares in the company, valued at $7,457,211.51. The trade was a 0.82% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 92,764 shares of company stock valued at $4,109,161 in the last quarter. Insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $44.00 on Monday. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.83 and a 12 month high of $54.23. The company’s fifty day moving average is $42.95 and its 200-day moving average is $44.64. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -21.78 and a beta of 0.95.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $111.59 million during the quarter, compared to the consensus estimate of $98.47 million. During the same quarter in the prior year, the company posted ($0.54) EPS. The firm’s revenue was up 61.2% on a year-over-year basis. Equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.